Top

Clinical Rheumatology

Published in:

01-05-2020 | Mastitis | Original Article

The clinical value of interleukins-8, -10, and -17 in idiopathic granulomatous mastitis

Authors: Hande Koksal, Husamettin Vatansev, Hasibe Artac, Naim Kadoglou

Published in: Clinical Rheumatology | Issue 5/2020

Abstract

Introduction

Idiopathic granulomatous mastitis (IGM) is a rare, chronic inflammatory benign breast disease. Although the etiology of this disease is unknown, it has been suggested that hormonal disorders, autoimmunity, smoking, and α1-antitrypsin deficiency may play a role in the etiopathogenesis. The aim is to investigate the changes in cytokine profiles including interleukin (IL)-4, -8, -10, -17, and tumor necrosis factor (TNF)-alpha in patients with IGM.

Methods

Forty-seven patients with pathologically diagnosed IGM and 30 healthy women were included. The cytokines including IL-4, -8, 10, -17, and TNF-alpha were measured by human enzyme-linked immunosorbent assay.

Results

The IL-8, IL-10, and IL-17 levels were higher in IGM patients than control group (p = .002; p = .008; and p = .018, respectively). The IL-8 levels of patients with active lesions and in remission were statistically higher than the control group (p = .027 and p = .015, respectively). IL-10 levels of patients in remission were higher than the control group (p = .024). There was no difference in IL-4 and TNF-ɑ levels between all groups.

Conclusion

These results showed that proinflammatory cytokines including IL-8 and IL-17 have role in pathogenesis of IGM. However, the increased levels of IL-10 in especially patients in remission suggest that it reduces the release of proinflamatory cytokines as well as suppressing their function and activation for controlling IGM. Although IGM is thought to be a surgical disease, these cytokine changes indicate the presence of serious immune dysregulation. This suggests that in the treatment of IGM, treatment needs to evolve from surgery to medical treatment.

Key points

• The IL-8, IL-10, and IL-17 levels were higher in IGM patients than in control group.

• The IL-8 levels of both patients with active lesions and in remission were high.

• There was no difference in IL-4 and TNF-ɑ levels between all groups.

Kessler E, Wolloch Y (1972) Granulomatous mastitis: a lesion clinically simulating carcinoma. Am J Clin Pathol 58:642–646CrossRef

Cohen C (1977) Granulomatous mastitis. A review of 5 cases. S Afr Med J 52:14–16PubMed

Altintoprak F, Kivilcim T, Ozkan OV (2014) Aetiology of idiopathic granulomatous mastitis. World J Clin Cases 2:852–858. https://doi.org/10.12998/wjcc.v2.i12.852 CrossRefPubMedPubMedCentral

Benson JR, Dumitru D (2016) Idiopathic granulomatous mastitis: presentation, investigation and management. Future Oncol 12:1381–1394. https://doi.org/10.2217/fon-2015-0038 CrossRefPubMed

Altintoprak F, Karakece E, Kivilcim T, Dikicier E, Cakmak G, Celebi F, Ciftci IH (2013) Idiopathic granulomatous mastitis: an autoimmune disease? ScientificWorldJournal 2013:148727. https://doi.org/10.1155/2013/148727 CrossRefPubMedPubMedCentral

Sheybani F, Naderi HR, Gharib M, Sarvghad M, Mirfeizi Z (2016) Idiopathic granulomatous mastitis: long-discussed but yet-to-be-known. Autoimmunity 49:236–239. https://doi.org/10.3109/08916934.2016.1138221 CrossRefPubMed

Ozel L, Unal A, Unal E, Kara M, Erdoğdu E, Krand O, Gunes P, Karagul H, Demiral S, Titiz MI (2012) Granulomatous mastitis: is it an autoimmune disease? Diagnostic and therapeutic dilemmas. Surg Today 42:729–733. https://doi.org/10.1007/s00595-011-0046-z CrossRefPubMed

Koksal H (2019) Human leukocyte antigens class I and II in patients with idiopathic granulomatous mastitis. Am J Surg 218:605–608. https://doi.org/10.1016/j.amjsurg.2019.01.038 CrossRefPubMed

Salesi M, Karimifar M, Salimi F, Mahzouni P (2011) A case of granulomatous mastitis with erythema nodosum and arthritis. Rheumatol Int 31:1093–1095. https://doi.org/10.1007/s00296-009-1273-0 CrossRefPubMed

10.

Binesh F, Shiryazdi M, Bagher Owlia M, Azimi S (2013) Idiopathic granulomatous mastitis, erythema nodosum and bilateral ankle arthritis in an Iranian woman. BMJ Case Rep. https://doi.org/10.1136/bcr-2012-007636

11.

Alungal J, Abdulla MC, Narayan R (2016) Idiopathic granulomatous mastitis with erythema nodosum and polyarthritis. Reumatismo 68:97–99. https://doi.org/10.4081/reumatismo.2016.844 CrossRefPubMed

12.

Zabetian S, Friedman BJ, McHargue C (2016) A case of idiopathic granulomatous mastitis associated with erythema nodosum, arthritis, and reactive cough. JAAD Case Rep 2:125–127. https://doi.org/10.1016/j.jdcr.2016.01.011 CrossRefPubMedPubMedCentral

13.

Akın M, Karabacak H, Esendağlı G, Yavuz A, Gültekin S, Dikmen K, Bostanci H (2017) Coexistence of idiopathic granulomatous mastitis and erythemanodosum: successful treatment with corticosteroids. Turk J Med Sci 47:1590–1592. https://doi.org/10.3906/sag-1611-100 CrossRefPubMed

14.

Fruchter R, Castilla C, Ng E, Pomeranz MK, Femia AN (2017) Erythema nodosum in association with idiopathic granulomatous mastitis: a case series and review of the literature. J Eur Acad Dermatol Venereol 31:e391–e393. https://doi.org/10.1111/jdv.14194 CrossRefPubMed

15.

Letourneux C, Diemunsch P, Korganow AS, Akladios CY, Bellocq JP, Mathelin C (2013) First report of granulomatous mastitis associated with Sjögren’s syndrome. World J Surg Oncol 11:268. https://doi.org/10.1186/1477-7819-11-268 CrossRefPubMedPubMedCentral

16.

Yigitbasi MR, Guntas G, Atak T, Sonmez C, Yalman H, Uzun H (2017) The role of interleukin-33 as an inflammatory marker in differential diagnosis of idiopathic granulomatous mastitis and breast cancer. J Investig Surg 30:272–276. https://doi.org/10.1080/08941939.2016.1240270 CrossRef

17.

Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI (2005) Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol 174:411–417. https://doi.org/10.4049/jimmunol.174.1.411 CrossRefPubMed

18.

Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Ouaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA (2011) Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 127:701–721. https://doi.org/10.1016/j.jaci.2010.11.050 CrossRefPubMed

19.

Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345–350. https://doi.org/10.1038/ni0407-345 CrossRefPubMed

20.

Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2015) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74:5–17. https://doi.org/10.1016/j.cyto.2014.09.011 CrossRefPubMed

21.

Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57:51–58. https://doi.org/10.1097/01.NNR.0000280655.58266.6c CrossRefPubMedPubMedCentral

22.

Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH (2013) Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 63:225–233. https://doi.org/10.1111/his.12156 CrossRefPubMed

Title: The clinical value of interleukins-8, -10, and -17 in idiopathic granulomatous mastitis
Authors: Hande Koksal
Husamettin Vatansev
Hasibe Artac
Naim Kadoglou
Publication date: 01-05-2020
Publisher: Springer London
Keywords: Mastitis
Cytokines
Published in: Clinical Rheumatology / Issue 5/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04925-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review

EULAR definition of “arthralgia suspicious for progression to rheumatoid arthritis” in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound

Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period

The impacts of resilience on the association between illness uncertainty and sleep quality among Chinese women with systemic lupus erythematosus

Implications of evaluating leg muscle mass and fat mass separately for quadriceps strength in knee osteoarthritis: the SPSS-OK study

Clinicopathological factors for tubulointerstitial injury in lupus nephritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials